The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

**Insulin Glargine (Insulin glargine-yfgn) Injection, 100 units/mL (U-100), 3 mL Prefilled Pen**

<table>
<thead>
<tr>
<th>NDC #</th>
<th>Name and Strength</th>
<th>Size</th>
<th>Batch #</th>
<th>Expiry</th>
</tr>
</thead>
<tbody>
<tr>
<td>49502-394-75</td>
<td>Insulin Glargine (Insulin glargine-yfgn) Injection, 100 units/mL (U-100)</td>
<td>3 mL Prefilled Pen</td>
<td>BF21002895</td>
<td>Aug 2023</td>
</tr>
</tbody>
</table>

Mylan Pharmaceuticals Inc. (a Viatris company) is conducting a recall at the consumer level of one batch, BF21002895, of Insulin Glargine (Insulin glargine-yfgn) Injection, 100 units/mL (U-100), 3 mL prefilled pens, which are packaged in cartons of 5 pens. This product is not the branded Semglee pen but the unbranded Insulin Glargine-yfgn pens. This batch is being recalled due to the potential for the label to be missing on some pens. The product information, batch number and expiry date information are present on the carton. This batch was distributed by Mylan Specialty L.P. in the US between April 4, 2022, and May 5, 2022.